CEPROTIN
| Product Specs | Description |
|---|---|
| Manufacturer Name | Takeda |
| Indications | For pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans. |
| Contraindications | None known |
| Manufacturing Methods | Protein C is the precursor of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulincomplex on the endothelial cell surface to activated Protein C (APC). APC is a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. |
| Viral Safety Process | Combination of filtration and chromatographic procedures including a column of immobilized mouse monoclonal antibodies on gel beads |
| Route of Administration | May be administered intravenously via sterile syringe or via an infusion bag |
| Product Half-Life | Initial Half-Life: 5.4 to 9.3 hours Terminal Half-Life: 7.0 to 12.4 hours |
| Storage Requirements/Shelf Life |
|
| Available Formulations | 500 IU/5 mL 1000 IU/10 mL |